Department of Neurosurgery and Gamma-Knife center, University of Virginia, Charlottesville, Virginia.
Department of Neurosurgery, Rambam Health Care Center Haifa Israel, Technion Israel Institute of Technology, Haifa, Israel.
Neurosurgery. 2017 Dec 1;81(6):910-920. doi: 10.1093/neuros/nyx189.
The management of brainstem arteriovenous malformations (bAVMs) is a formidable challenge. bAVMs harbor higher morbidity and mortality compared to other locations.
To review the outcomes following stereotactic radiosurgery (SRS) of bAVMs in a multicenter study.
Six medical centers contributed data from 205 patients through the International Gamma Knife Research Foundation. Median age was 32 yr (6-81). Median nidus volume was 1.4 mL (0.1-69 mL). Favorable outcome (FO) was defined as AVM obliteration and no post-treatment hemorrhage or permanent symptomatic radiation-induced complications.
Overall obliteration was reported in 65.4% (n = 134) at a mean follow-up of 69 mo. Obliteration was angiographically proven in 53.2% (n = 109) and on MRA in 12.2% (n = 25). Actuarial rate of obliteration at 2, 3, 5, 7, and 10 yr after SRS was 24.5%, 43.3%, 62.3%, 73%, and 81.8% respectively. Patients treated with a margin dose >20 Gy were more likely to achieve obliteration (P = .001). Obliteration occurred earlier in patients who received a higher prescribed margin dose (P = .05) and maximum dose (P = .041). Post-SRS hemorrhage occurred in 8.8% (n = 18). Annual postgamma knife latency period hemorrhage was 1.5%. Radiation-induced complications were radiologically evident in 35.6% (n = 73), symptomatic in 14.6% (n = 30), and permanent in 14.6% (n = 30, which included long-tract signs and new cranial nerve deficits). FO was achieved in 64.4% (n = 132). Predictors of an FO were a higher Virginia radiosurgery AVM scale score (P = .003), prior hemorrhage (P = .045), and a lower prescribed maximum dose (P = .006).
SRS for bAVMs results in obliteration and avoids permanent complications in the majority of patients.
脑干动静脉畸形(bAVM)的治疗是一项艰巨的挑战。与其他部位相比,bAVM 具有更高的发病率和死亡率。
通过国际伽玛刀研究基金会,在多中心研究中回顾立体定向放射外科(SRS)治疗 bAVM 的结果。
六家医疗中心通过国际伽玛刀研究基金会提供了 205 名患者的数据。中位年龄为 32 岁(6-81 岁)。中位病灶体积为 1.4 毫升(0.1-69 毫升)。良好结局(FO)定义为 AVM 闭塞且无治疗后出血或永久性症状性放射性诱导并发症。
在平均 69 个月的随访中,总体闭塞率为 65.4%(n=134)。在 53.2%(n=109)的患者中通过血管造影证实了闭塞,在 12.2%(n=25)的患者中通过 MRA 证实了闭塞。SRS 后 2、3、5、7 和 10 年的闭塞累积发生率分别为 24.5%、43.3%、62.3%、73%和 81.8%。接受边缘剂量>20Gy 治疗的患者更有可能实现闭塞(P=0.001)。接受更高处方边缘剂量(P=0.05)和最大剂量(P=0.041)的患者更早出现闭塞。SRS 后出血发生率为 8.8%(n=18)。每年伽玛刀潜伏期出血率为 1.5%。35.6%(n=73)的患者出现放射影像学上明显的放射性并发症,14.6%(n=30)出现症状性并发症,14.6%(n=30)出现永久性并发症,包括长束征和新的颅神经缺损。FO 率为 64.4%(n=132)。FO 的预测因素包括较高的弗吉尼亚放射外科 AVM 量表评分(P=0.003)、既往出血(P=0.045)和较低的处方最大剂量(P=0.006)。
SRS 治疗 bAVM 可使大多数患者实现闭塞,并避免永久性并发症。